PDF(Pubmed)
Abstract：
Obesity is in epidemic proportions in many parts of the world, contributing to increasing rates of non-alcoholic fatty liver disease (NAFLD). NAFLD represents a range of conditions from the initial stage of fatty liver to non-alcoholic steatohepatitis (NASH), which can progress to severe fibrosis, through to hepatocellular carcinoma. There currently exists no treatment for the long-term management of NAFLD/NASH, however, dietary interventions have been investigated for the treatment of NASH, including several polyphenolic compounds. Ellagic acid is one such polyphenolic compound. Nutraceutical food abundant in ellagic acid undergoes initial hydrolysis to free ellagic acid within the stomach and small intestine. The proposed mechanism of action of ellagic acid extends beyond its initial therapeutic potential, as it is further broken down by the gut microbiome into urolithin. Both ellagic acid and urolithin have been found to alleviate oxidative stress, inflammation, and fibrosis, which are associated with NAFLD/NASH. While progress has been made in understanding the pharmacological and biological activity of ellagic acid and its involvement in NAFLD/NASH, it has yet to be fully elucidated. Thus, the aim of this review is to summarise the currently available literature elucidating the therapeutic potential of ellagic acid and its microbial-derived metabolite urolithin in NAFLD/NASH.
摘要：
肥胖在世界许多地方都是流行病，有助于增加非酒精性脂肪性肝病（NAFLD）的发病率。NAFLD代表从脂肪肝的初始阶段到非酒精性脂肪性肝炎（NASH）的一系列疾病，可以进展为严重的纤维化，通过肝细胞癌。目前没有治疗NAFLD/NASH的长期管理，然而,已经研究了饮食干预来治疗NASH，包括几种多酚化合物。鞣花酸是一种这样的多酚化合物。富含鞣花酸的营养食品在胃和小肠内经历初始水解为游离鞣花酸。鞣花酸的作用机制超出了其最初的治疗潜力，因为它被肠道微生物组进一步分解为尿石素。鞣花酸和尿石素都被发现可以缓解氧化应激，炎症,和纤维化，与NAFLD/NASH相关。虽然在了解鞣花酸的药理和生物活性及其在NAFLD/NASH中的参与方面取得了进展，它尚未得到充分阐明。因此，这篇综述的目的是总结现有文献,阐明鞣花酸及其微生物来源的代谢产物尿石素在NAFLD/NASH中的治疗潜力.
